

Domingo Pascual-Figal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4786359/publications.pdf>

Version: 2024-02-01

241
papers

11,744
citations

28190

55
h-index

33814

99
g-index

277
all docs

277
docs citations

277
times ranked

12738
citing authors

#	ARTICLE	IF	CITATIONS
1	Is there sufficient evidence to justify changes in dietary habits in heart failure patients? A systematic review. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 37-47.	0.7	4
2	Critical warm ischemia time point for cardiac donation after circulatory death. <i>American Journal of Transplantation</i> , 2022, 22, 1321-1328.	2.6	16
3	Prevalence, Incidence, and Outcomes of Hyperkalemia in Patients with Chronic Heart Failure and Reduced Ejection Fraction from a Spanish Multicentre Study: SPANIK-HF Design and Baseline Characteristics. <i>Journal of Clinical Medicine</i> , 2022, 11, 1170.	1.0	2
4	Unnecessary Use of Corticosteroids for managing early mild symptoms of COVID-19 may lead to Rhino-orbital-cerebral mucormycosis in Patients with Diabetes – a case series from Lahore, Pakistan. <i>Therapeutic Advances in Infectious Disease</i> , 2022, 9, 204993612210974.	1.1	5
5	Environmental factors like air pollution: not to be forgotten in the 2021 ESC guidelines on heart failure. <i>Response. Revista Espanola De Cardiologia (English Ed)</i> , 2022, 75, 539-539.	0.4	0
6	Colchicine for the treatment of coronary artery disease. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 497-504.	2.3	10
7	Prognostic impact of hyponatraemia and hypernatraemia at admission and discharge in heart failure patients with preserved, mid-range and reduced ejection fraction. <i>Internal Medicine Journal</i> , 2021, 51, 930-938.	0.5	12
8	The miRNA199a/SIRT1/P300/Yy1/sST2 signaling axis regulates adverse cardiac remodeling following MI. <i>Scientific Reports</i> , 2021, 11, 3915.	1.6	6
9	Biochemical or clinical heart failure, not so simple. <i>European Journal of Heart Failure</i> , 2021, 23, 465-467.	2.9	1
10	Clonal Hematopoiesis and Risk of Progression of Heart Failure With Reduced Left Ventricular Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1747-1759.	1.2	111
11	Ischemic Etiology and Prognosis in Men and Women with Acute Heart Failure. <i>Journal of Clinical Medicine</i> , 2021, 10, 1713.	1.0	4
12	Prevalence and characteristics of clonal hematopoiesis in heart failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 996-999.	0.4	5
13	Colchicine in Recently Hospitalized Patients with COVID-19: A Randomized Controlled Trial (COL-COVID). <i>International Journal of General Medicine</i> , 2021, Volume 14, 5517-5526.	0.8	25
14	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. <i>European Heart Journal</i> , 2021, 42, 3011-3020.	1.0	71
15	A 3-Biomarker 2-Point-Based Risk Stratification Strategy in Acute Heart Failure. <i>Frontiers in Physiology</i> , 2021, 12, 708890.	1.3	3
16	Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 754499.	1.1	30
17	Non-biopsy diagnosis of familial amyloid cardiomyopathy. <i>Journal of Nuclear Cardiology</i> , 2020, 27, 1394-1397.	1.4	1
18	Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 313-323.	0.4	10

#	ARTICLE	IF	CITATIONS
19	Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study. <i>European Journal of Heart Failure</i> , 2020, 22, 303-312.	2.9	52
20	Economic analysis of intermittent intravenous outpatient treatment with levosimendan in advanced heart failure in Spain. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 361-367.	0.4	2
21	Hiperpotasemia en pacientes con insuficiencia cardiaca en España y su impacto en las recomendaciones. Registro ESC-EORP-HFA Heart Failure Long-Term. <i>Revista Espanola De Cardiologia</i> , 2020, 73, 313-323.	0.6	16
22	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. <i>Lancet, The</i> , 2020, 396, 1895-1904.	6.3	425
23	NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 822-833.	1.9	21
24	Impact of pre-hospital renal function on the detection of acute kidney injury in acute decompensated heart failure. <i>European Journal of Internal Medicine</i> , 2020, 77, 66-72.	1.0	10
25	Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study. <i>ESC Heart Failure</i> , 2020, 7, 559-566.	1.4	15
26	Incidence, prognosis and predictors of heart failure after acute myocardial infarction. <i>REC: CardioClinics</i> , 2020, 55, 8-14.	0.1	5
27	Análisis económico del tratamiento ambulatorio intermitente con levosimendán de la insuficiencia cardiaca avanzada en España. <i>Revista Espanola De Cardiologia</i> , 2020, 73, 361-367.	0.6	8
28	Estudio poblacional de la primera hospitalización por insuficiencia cardiaca y la interacción entre los reingresos y la supervivencia. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 740-748.	0.6	15
29	Role of Beta-blockers in Cardiovascular Disease in 2019. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 844-852.	0.4	18
30	Papel de los bloqueadores beta en la enfermedad cardiovascular en 2019. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 844-852.	0.6	20
31	Reply. <i>Journal of the American College of Cardiology</i> , 2019, 74, 479-480.	1.2	0
32	Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes. <i>JACC Basic To Translational Science</i> , 2019, 4, 831-840.	1.9	65
33	Effect of concomitant antiplatelet therapy in patients with nonvalvular atrial fibrillation initiating nonvitamin K antagonists. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13161.	1.7	5
34	Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. <i>European Journal of Heart Failure</i> , 2019, 21, 998-1007.	2.9	233
35	Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world. <i>European Journal of Heart Failure</i> , 2019, 21, 1383-1397.	2.9	35
36	Acute heart failure congestion and perfusion status: Impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2019, 21, 1338-1352.	2.9	170

#	ARTICLE	IF	CITATIONS
37	Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure. <i>International Journal of Cardiology</i> , 2019, 293, 137-142.	0.8	24
38	Yin-Yang 1 transcription factor modulates ST2 expression during adverse cardiac remodeling post-myocardial infarction. <i>Journal of Molecular and Cellular Cardiology</i> , 2019, 130, 216-233.	0.9	14
39	Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. <i>Circulation</i> , 2019, 140, 31-41.	1.6	195
40	Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction. <i>Internal Medicine Journal</i> , 2019, 49, 1505-1513.	0.5	15
41	The Interleukin-1 Axis and Risk of Death in Patients With Acutely Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1016-1025.	1.2	52
42	Effectiveness and safety of rivaroxaban in nonvalvular atrial fibrillation: data from a contemporary Spanish registry. <i>Current Medical Research and Opinion</i> , 2019, 35, 1463-1471.	0.9	3
43	Galectina-3 como biomarcador de riesgo de daño renal agudo en pacientes con insuficiencia cardiaca descompensada. <i>Revista Clinica Espanola</i> , 2019, 219, 315-319.	0.2	2
44	Hospitalización: el momento más vulnerable. <i>Revista Espanola De Cardiologia Suplementos</i> , 2019, 18, 17-23.	0.2	0
45	Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1651-1658.	2.9	42
46	Lack of improvement in autonomic cardiac tone after sacubitril/valsartan at lower than target doses. <i>Journal of Electrocardiology</i> , 2019, 52, 99-100.	0.4	1
47	Prevalencia e implicación pronóstica de la enfermedad valvular en pacientes con fibrilación auricular que inician anticoagulantes orales. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 935-943.	0.6	0
48	Population-based Study of First Hospitalizations for Heart Failure and the Interaction Between Readmissions and Survival. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 740-748.	0.4	7
49	Temporal characterization of cardiac expression of glucose transporters SGLT and GLUT in an experimental model of myocardial infarction. <i>Diabetes and Metabolism</i> , 2019, 45, 201-204.	1.4	1
50	Inervación simpática cardiaca y terapias apropiadas en pacientes portadores de desfibrilador automático implantado en prevención primaria. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 180-182.	0.6	1
51	Cardiac Sympathetic Innervation and Appropriate Therapies in Patients With an Implantable Cardioverter-defibrillator in Primary Prevention. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 180-182.	0.4	0
52	Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. <i>European Journal of Heart Failure</i> , 2018, 20, 1128-1136.	2.9	134
53	Análisis de los ingresos hospitalarios por insuficiencia cardiaca en registros sanitarios de diferentes comunidades autónomas. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 128-129.	0.6	1
54	Analysis of Hospitalization Trends for Heart Failure in the Health Registries of Different Autonomous Communities. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 128-129.	0.4	0

#	ARTICLE	IF	CITATIONS
55	Pharmacological inhibition of the mitochondrial NADPH oxidase 4/PKC β /Gal-3 pathway reduces left ventricular fibrosis following myocardial infarction. <i>Translational Research</i> , 2018, 199, 4-23.	2.2	20
56	Short-term Serial Measurement of Galectin-3 in Hospitalized Patients With Acute Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 401-402.	0.4	1
57	Valores seriados de galectina-3 a corto plazo en pacientes hospitalizados por insuficiencia cardiaca aguda. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 401-402.	0.6	1
58	Rationale and design of <i>TRANSITION</i> : a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan. <i>ESC Heart Failure</i> , 2018, 5, 327-336.	1.4	42
59	Pulmonary Production of Soluble ST2 in Heart Failure. <i>Circulation: Heart Failure</i> , 2018, 11, e005488.	1.6	52
60	Sacubitril/Valsartan Initiated in Hospitalized Patients with Heart Failure with Reduced Ejection Fraction after Hemodynamic Stabilization: Primary Results of the <i>TRANSITION</i> Study. <i>Journal of Cardiac Failure</i> , 2018, 24, S15.	0.7	3
61	Noncardiac Production of Soluble ST2 in ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1429-1430.	1.2	9
62	Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry. <i>JACC: Heart Failure</i> , 2018, 6, 452-462.	1.9	94
63	Genetic Etiology for Alcohol-Induced Cardiac Toxicity. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2293-2302.	1.2	182
64	The misperception of "stable" heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1375-1378.	2.9	9
65	Testosterone Replacement Therapy in Deficient Patients With Chronic Heart Failure. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 543-550.	1.0	16
66	Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population. <i>International Journal of Cardiology</i> , 2018, 270, 192-196.	0.8	69
67	Early serum creatinine changes and outcomes in patients admitted for acute heart failure: the cardio-renal syndrome revisited. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 430-440.	0.4	21
68	Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 685-696.	0.4	49
69	La fracción de eyección intermedia no permite estratificar el riesgo de los pacientes hospitalizados por insuficiencia cardiaca. <i>Revista Espanola De Cardiologia</i> , 2017, 70, 338-346.	0.6	47
70	Predictive capacity of a multimarker strategy to determine short-term mortality in patients attending a hospital emergency Department for acute heart failure. <i>BIO-EAHFE</i> study. <i>Clinica Chimica Acta</i> , 2017, 466, 22-30.	0.5	13
71	Meta-Analysis of Soluble Suppression of <i>Tumorigenicity-2</i> and Prognosis in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 287-296.	1.9	104
72	Acute heart failure and biomarkers: time also matters, don't relax. <i>European Journal of Heart Failure</i> , 2017, 19, 1011-1013.	2.9	1

#	ARTICLE	IF	CITATIONS
73	Trends and Characteristics of Hospitalization for Heart Failure in a Population Setting From 2003 to 2013. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 720-726.	0.4	10
74	Concentración de relaxina en pacientes con insuficiencia cardiaca aguda. Respuesta. <i>Revista Espanola De Cardiologia</i> , 2017, 70, 516-517.	0.6	0
75	Mid-range left ventricular ejection fraction: Clinical profile and cause of death in ambulatory patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2017, 240, 265-270.	0.8	66
76	Mid-range Ejection Fraction Does Not Permit Risk Stratification Among Patients Hospitalized for Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 338-346.	0.4	29
77	A Novel Founder Mutation in MYBPC3: Phenotypic Comparison With the Most Prevalent MYBPC3 Mutation in Spain. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 105-114.	0.4	10
78	Neprilysin and Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2154-2156.	1.2	4
79	Early Anti-inflammatory and Pro-angiogenic Myocardial Effects of Intravenous Serelaxin Infusion for 72h in an Experimental Rat Model of Acute Myocardial Infarction. <i>Journal of Cardiovascular Translational Research</i> , 2017, 10, 460-469.	1.1	7
80	Relaxin Concentrations in Acute Heart Failure Patients. Response. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 516-517.	0.4	0
81	Comentarios a los nuevos criterios internacionales para la interpretación del electrocardiograma del deportista. <i>Revista Espanola De Cardiologia</i> , 2017, 70, 983-990.	0.6	0
82	Trends, causes and timing of 30-day readmissions after hospitalization for heart failure: 11-year population-based analysis with linked data. <i>International Journal of Cardiology</i> , 2017, 248, 246-251.	0.8	34
83	Rationale and design of a multicentre, prospective, randomised, controlled clinical trial to evaluate the efficacy of the adipose graft transposition procedure in patients with a myocardial scar: the AGTP II trial. <i>BMJ Open</i> , 2017, 7, e017187.	0.8	9
84	Doxorubicin-induced oxidative stress: The protective effect of nicorandil on HL-1 cardiomyocytes. <i>PLoS ONE</i> , 2017, 12, e0172803.	1.1	96
85	No benefit from the obesity paradox for diabetic patients with heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 851-858.	2.9	49
86	Serum neprilysin and recurrent hospitalizations after acute heart failure. <i>International Journal of Cardiology</i> , 2016, 220, 742-744.	0.8	12
87	Comments on the 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 1119-1125.	0.4	10
88	Documento de consenso y recomendaciones sobre el uso de los péptidos natriuréticos en la práctica clínica. <i>Revista Clinica Espanola</i> , 2016, 216, 313-322.	0.2	15
89	Early oxidative damage induced by doxorubicin: Source of production, protection by GKT137831 and effect on Ca ²⁺ transporters in HL-1 cardiomyocytes. <i>Archives of Biochemistry and Biophysics</i> , 2016, 594, 26-36.	1.4	31
90	Factor de transcripción TBX1 en el remodelado cardiaco asociado al infarto de miocardio. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 1042-1050.	0.6	1

#	ARTICLE	IF	CITATIONS
91	The TBX1 Transcription Factor in Cardiac Remodeling After Myocardial Infarction. Revista Espanola De Cardiologia (English Ed), 2016, 69, 1042-1050.	0.4	0
92	Mutation in <sc>JPH2</sc> cause dilated cardiomyopathy. Clinical Genetics, 2016, 90, 468-469.	1.0	20
93	Relaxin Concentrations in Acute Heart Failure Patients: Kinetics and Clinical Determinants. Revista Espanola De Cardiologia (English Ed), 2016, 69, 1230-1232.	0.4	5
94	Cancer Incidence in Heart Transplant Recipients With Previous Neoplasia History. American Journal of Transplantation, 2016, 16, 1569-1578.	2.6	12
95	Usefulness of the Hepatocyte Growth Factor as a Predictor of Mortality in Patients Hospitalized With Acute Heart Failure Regardless of Ejection Fraction. American Journal of Cardiology, 2016, 118, 543-549.	0.7	6
96	Natriuretic Peptides: Consensus Call for Use. Revista Espanola De Cardiologia (English Ed), 2016, 69, 817-819.	0.4	3
97	Quality markers in cardiology: measures of outcomes and clinical practiceâ€”a perspective of the Spanish Society of Cardiology and of Thoracic and Cardiovascular Surgery. European Heart Journal, 2016, 37, 12-23.	1.0	14
98	Ausencia de implicaci3n de la cistatina C en el remodelado ventricular y la insuficiencia cardiaca. Revista Clinica Espanola, 2016, 216, 55-61.	0.2	2
99	Reformulated meat products protect against ischemia-induced cardiac damage. Food and Function, 2016, 7, 992-1001.	2.1	2
100	Genetic basis of familial dilated cardiomyopathy patients undergoing heart transplantation. Journal of Heart and Lung Transplantation, 2016, 35, 625-635.	0.3	60
101	Clinical relevance of sST2 in cardiac diseases. Clinical Chemistry and Laboratory Medicine, 2016, 54, 29-35.	1.4	57
102	Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: results from the MAGGIC individual patient data meta-analysis. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 377-382.	0.2	28
103	A simple validated method for predicting the risk of hospitalization for worsening of heart failure in ambulatory patients: the Redinâ€”SCORE. European Journal of Heart Failure, 2015, 17, 818-827.	2.9	50
104	Quality markers in cardiology: measures of outcomes and clinical practice â€”a perspective of the Spanish Society of Cardiology and of Thoracic and Cardiovascular Surgery1. Cirugia Cardiovascular, 2015, 22, 315-324.	0.1	0
105	Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the <sc>MAGGIC</sc> metaâ€”analysis. European Journal of Heart Failure, 2015, 17, 1182-1191.	2.9	48
106	Healthâ€”related quality of life, social support, and caregiver burden between six and 120Â”months after heart transplantation: a Spanish multicenter crossâ€”sectional study. Clinical Transplantation, 2015, 29, 771-780.	0.8	25
107	Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. European Heart Journal, 2015, 36, 1106-1114.	1.0	53
108	Cystatin Câ€”based <sc>CKDâ€”EPI</sc> Equations and Nâ€”Terminal Proâ€”Type Natriuretic Peptide for Predicting Outcomes in Acutely Decompensated Heart Failure. Clinical Cardiology, 2015, 38, 106-113.	0.7	17

#	ARTICLE	IF	CITATIONS
109	Influencia del perfil clínico del donante, receptor y tiempo de isquemia en la supervivencia del trasplante cardíaco. Subanálisis del Registro Español de Trasplante Cardíaco. <i>Cirugía Cardiovascular</i> , 2015, 22, 279-286.	0.1	0
110	The Biology of ST2: The International ST2 Consensus Panel. <i>American Journal of Cardiology</i> , 2015, 115, 3B-7B.	0.7	216
111	Donor/recipient sex mismatch and survival after heart transplantation: only an issue in male recipients? An analysis of the Spanish Heart Transplantation Registry. <i>Transplant International</i> , 2015, 28, 305-313.	0.8	35
112	Galectin-3 and post-myocardial infarction cardiac remodeling. <i>European Journal of Pharmacology</i> , 2015, 763, 115-121.	1.7	63
113	ST2 Testing for Chronic Heart Failure Therapy Monitoring: The International ST2 Consensus Panel. <i>American Journal of Cardiology</i> , 2015, 115, 70B-75B.	0.7	80
114	Informe del Registro Español de Tumores Postrasplante Cardíaco. <i>Revista Española De Cardiología Suplementos</i> , 2015, 15, 50-57.	0.2	1
115	Evaluation of the preoperative vasoactive-inotropic score as a predictor of postoperative outcomes in patients undergoing heart transplantation. <i>International Journal of Cardiology</i> , 2015, 185, 192-194.	0.8	25
116	Serial ST2 Testing in Hospitalized Patients With Acute Heart Failure. <i>American Journal of Cardiology</i> , 2015, 115, 32B-37B.	0.7	29
117	Quality Markers in Cardiology. Main Markers to Measure Quality of Results (Outcomes) and Quality Measures Related to Better Results in Clinical Practice (Performance Metrics). <i>INCARDIO (Indicadores) Tj ETQq1 1 0,784314 rrgBT /Ov</i> <i>Revista Española De Cardiología (English Ed.)</i> , 2015, 68, 976-995.e10.	0.4	15
118	Prognostic Value and Kinetics of Soluble Natriuretic Peptide Receptor Type 1 in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 641-644.	1.9	44
119	Prognostic markers of acute decompensated heart failure: The emerging roles of cardiac biomarkers and prognostic scores. <i>Archives of Cardiovascular Diseases</i> , 2015, 108, 64-74.	0.7	32
120	Mineralocorticoid Receptor Antagonists Modulate Galectin-3 and Interleukin-33/ST2 Signaling in Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction. <i>JACC: Heart Failure</i> , 2015, 3, 50-58.	1.9	77
121	Twelve-month efficacy and safety of the conversion to everolimus in maintenance heart transplant recipients. <i>World Journal of Transplantation</i> , 2015, 5, 310.	0.6	9
122	The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data. <i>International Journal of Obesity</i> , 2014, 38, 1110-1114.	1.6	155
123	Modulation of IL-33/ST2 system in postinfarction heart failure: correlation with cardiac remodelling markers. <i>European Journal of Clinical Investigation</i> , 2014, 44, 643-651.	1.7	57
124	The falling incidence of hematologic cancer after heart transplantation. <i>Clinical Transplantation</i> , 2014, 28, 1142-1147.	0.8	5
125	Ferritin heavy chain as main mediator of preventive effect of metformin against mitochondrial damage induced by doxorubicin in cardiomyocytes. <i>Free Radical Biology and Medicine</i> , 2014, 67, 19-29.	1.3	24
126	Health Care and Nonhealth Care Costs in the Treatment of Patients With Symptomatic Chronic Heart Failure in Spain. <i>Revista Española De Cardiología (English Ed.)</i> , 2014, 67, 643-650.	0.4	38

#	ARTICLE	IF	CITATIONS
127	Prognostic Value of Body Mass Index and Waist Circumference in Patients With Chronic Heart Failure (Spanish REDINSCOR Registry). <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 101-106.	0.4	11
128	Galectin-3 expression in cardiac remodeling after myocardial infarction. <i>International Journal of Cardiology</i> , 2014, 172, e98-e101.	0.8	51
129	Adiponectin and p53 mRNA in epicardial and subcutaneous fat from heart failure patients. <i>European Journal of Clinical Investigation</i> , 2014, 44, 29-37.	1.7	21
130	Impact of short-term mechanical circulatory support with extracorporeal devices on postoperative outcomes after emergency heart transplantation: Data from a multi-institutional Spanish cohort. <i>International Journal of Cardiology</i> , 2014, 176, 86-93.	0.8	29
131	Body Mass Index and Mortality in Acutely Decompensated Heart Failure Across the World. <i>Journal of the American College of Cardiology</i> , 2014, 63, 778-785.	1.2	213
132	Valor pronóstico del Índice de masa corporal y el perímetro de cintura en los pacientes con insuficiencia cardiaca crónica (Registro Español REDINSCOR). <i>Revista Espanola De Cardiologia</i> , 2014, 67, 101-106.	0.6	20
133	Chronic Renal Dysfunction in Maintenance Heart Transplant Patients: The ICEBERG Study. <i>Transplantation Proceedings</i> , 2014, 46, 14-20.	0.3	22
134	Costes sanitarios y no sanitarios de personas que padecen insuficiencia cardiaca crónica sintomática en España. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 643-650.	0.6	103
135	Differential behavior between S100A9 and adiponectin in coronary artery disease. Plasma or epicardial fat. <i>Life Sciences</i> , 2014, 100, 147-151.	2.0	5
136	Red Blood Cell Distribution Width Is Longitudinally Associated With Mortality and Anemia in Heart Failure Patients. <i>Circulation Journal</i> , 2014, 78, 410-418.	0.7	37
137	Prognostic markers for acute heart failure. <i>Expert Opinion on Medical Diagnostics</i> , 2013, 7, 379-392.	1.6	11
138	Primary graft failure after heart transplantation: Characteristics in a contemporary cohort and performance of the RADIAL risk score. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 1187-1195.	0.3	89
139	Heart rate control in chronic heart failure: Resting versus mean heart rate with prolonged ambulatory ECG recording. <i>International Journal of Cardiology</i> , 2013, 170, e45-e47.	0.8	9
140	High sensitive cardiac troponin T in the management of uncertain chest pain. <i>International Journal of Cardiology</i> , 2013, 168, 4422-4423.	0.8	2
141	Involvement of ferritin heavy chain in the preventive effect of metformin against doxorubicin-induced cardiotoxicity. <i>Free Radical Biology and Medicine</i> , 2013, 57, 188-200.	1.3	38
142	Known and missing left ventricular ejection fraction and survival in patients with heart failure: a MAGGIC meta-analysis report. <i>European Journal of Heart Failure</i> , 2013, 15, 1220-1227.	2.9	28
143	Association Between Elevated Blood Glucose and Outcome in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 820-829.	1.2	111
144	Spirolactone in mild chronic heart failure: Insights from a propensity-matched analysis of the MUSIC study cohort. <i>International Journal of Cardiology</i> , 2013, 168, 4525-4527.	0.8	3

#	ARTICLE	IF	CITATIONS
145	Comparison of Risk Prediction With the CKD-EPI and MDRD Equations in Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2013, 19, 583-591.	0.7	41
146	Post-transplant increase in soluble human leukocyte antigen-G associated with non-severe cardiac allograft vasculopathy. <i>Human Immunology</i> , 2013, 74, 318-324.	1.2	10
147	Renal function measurements and mortality in patients with acute heart failure. <i>International Journal of Cardiology</i> , 2013, 168, 4990-4991.	0.8	6
148	Treatment of Anemia with Darbeoetin Alfa in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2013, 368, 1210-1219.	13.9	462
149	Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study. <i>International Journal of Cardiology</i> , 2013, 168, 2186-2194.	0.8	207
150	Preoperative INTERMACS Profiles Determine Postoperative Outcomes in Critically Ill Patients Undergoing Emergency Heart Transplantation. <i>Circulation: Heart Failure</i> , 2013, 6, 763-772.	1.6	60
151	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2013, 15, 1173-1184.	2.9	533
152	Differential clinical characteristics and prognosis of intraventricular conduction defects in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2013, 15, 877-884.	2.9	27
153	Baseline characteristics of patients in the Reduction of Events with Darbeoetin alfa in Heart Failure trial (RED-CHF). <i>European Journal of Heart Failure</i> , 2013, 15, 334-341.	2.9	24
154	Serial Monitoring of Soluble Interleukin Family Member ST2 in Patients with Acutely Decompensated Heart Failure. <i>Cardiology</i> , 2012, 122, 158-166.	0.6	67
155	Renal Dysfunction in Patients With Heart Failure With Preserved Versus Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2012, 5, 309-314.	1.6	152
156	The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. <i>European Heart Journal</i> , 2012, 33, 1750-1757.	1.0	652
157	Prognostic Significance of Long-Period Heart Rate Rhythms in Chronic Heart Failure. <i>Circulation Journal</i> , 2012, 76, 2124-2129.	0.7	4
158	Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: an individual patient data meta-analysis. <i>European Journal of Heart Failure</i> , 2012, 14, 1139-1146.	2.9	100
159	Soluble TNF α receptor type I and hepcidin as determinants of development of anemia in the long-term follow-up of heart failure patients. <i>Clinical Biochemistry</i> , 2012, 45, 1455-1458.	0.8	12
160	Differences in Outcome of Heart Failure With Preserved or Depressed Systolic Function in Patients Older Than 70 Years Who Receive Beta Blockers. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 22-28.	0.4	1
161	Red Blood Cell Distribution Width Adds Prognostic Value for Outpatients With Chronic Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 606-612.	0.4	14
162	Comments on the ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012. A Report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 874-878.	0.4	7

#	ARTICLE	IF	CITATIONS
163	Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta-analysis. European Journal of Heart Failure, 2012, 14, 473-479.	2.9	167
164	El ancho de distribución eritrocitaria aporta valor pronóstico adicional en pacientes ambulatorios con insuficiencia cardiaca crónica. Revista Española De Cardiología, 2012, 65, 606-612.	0.6	29
165	Highly sensitive troponin T for risk stratification of acutely destabilized heart failure. American Heart Journal, 2012, 163, 1002-1010.	1.2	72
166	Optical Coherence Tomography and Highly Sensitivity Troponin T for Evaluating Cardiac Allograft Vasculopathy. American Journal of Cardiology, 2012, 110, 655-661.	0.7	47
167	672 The Incidence of Hematologic Cancer after Heart Transplantation Has Declined in the Last Decade. Data from the Spanish Post-Heart Transplant Tumor Registry. Journal of Heart and Lung Transplantation, 2012, 31, S231.	0.3	0
168	Red blood cell distribution width predicts new-onset anemia in heart failure patients. International Journal of Cardiology, 2012, 160, 196-200.	0.8	35
169	Prognostic value of serum cystatin C and N-terminal pro b-type natriuretic peptide in patients with acute heart failure. European Journal of Internal Medicine, 2012, 23, 599-603.	1.0	28
170	Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. European Journal of Heart Failure, 2011, 13, 718-725.	2.9	228
171	Î2-Trace Protein and Cystatin C as Predictors of Long-Term Outcomes in Patients With Acute Heart Failure. Journal of the American College of Cardiology, 2011, 57, 849-858.	1.2	66
172	Eplerenone in Mild Heart Failure. New England Journal of Medicine, 2011, 364, 1370-1372.	18.9	3
173	Passive Ca ²⁺ overload in H9c2 cardiac myoblasts: Assessment of cellular damage and cytosolic Ca ²⁺ transients. Archives of Biochemistry and Biophysics, 2011, 512, 175-182.	1.4	2
174	Obesity paradox and risk of sudden death in heart failure. American Heart Journal, 2011, 161, 158-164.	1.2	30
175	Short-Term Variability of Heart Rate Turbulence in Chronic Heart Failure. Journal of Cardiac Failure, 2011, 17, 735-741.	0.7	6
176	CD28 and KIR2D receptors as sensors of the immune status in heart and liver transplantation. Human Immunology, 2011, 72, 841-848.	1.2	15
177	Comparative Prognostic Value of Plasma and Urinary N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Acute Destabilized Heart Failure. Revista Española De Cardiología (English Ed), 2011, 64, 365-372.	0.4	1
178	Aldosterone Receptor Antagonist Use After Myocardial Infarction. Data From the REICIAM Registry. Revista Española De Cardiología (English Ed), 2011, 64, 981-987.	0.4	4
179	Usefulness of High Sensitivity Troponin T Assay in Detecting Acute Allograft Rejection After Heart Transplantation. Revista Española De Cardiología (English Ed), 2011, 64, 1109-1113.	0.4	5
180	Risk factors associated with cytomegalovirus infection in heart transplant patients: a prospective, epidemiological study. Transplant Infectious Disease, 2011, 13, 136-144.	0.7	25

#	ARTICLE	IF	CITATIONS
181	Lung Cancer after Heart Transplantation: Results from a Large Multicenter Registry. American Journal of Transplantation, 2011, 11, 1035-1040.	2.6	29
182	Effects of Prolonged-Release Torasemide Versus Furosemide on Myocardial Fibrosis in Hypertensive Patients with Chronic Heart Failure: A Randomized, Blinded End Point, Active-Controlled Study. Clinical Therapeutics, 2011, 33, 1204-1213.e3.	1.1	33
183	Usefulness of Soluble Concentrations of Interleukin Family Member ST2 as Predictor of Mortality in Patients With Acutely Decompensated Heart Failure Relative to Left Ventricular Ejection Fraction. American Journal of Cardiology, 2011, 107, 259-267.	0.7	185
184	Anabolic Status and Functional Impairment in Men With Mild Chronic Heart Failure. American Journal of Cardiology, 2011, 108, 862-866.	0.7	13
185	Metformin protects against doxorubicin-induced cardiotoxicity: Involvement of the adiponectin cardiac system. Free Radical Biology and Medicine, 2011, 51, 1861-1871.	1.3	85
186	Soluble ST2 Is a Marker for Acute Cardiac Allograft Rejection. Annals of Thoracic Surgery, 2011, 92, 2118-2124.	0.7	41
187	Heart Rate Variability on 7-Day Holter Monitoring Using a Bootstrap Rhythmometric Procedure. IEEE Transactions on Biomedical Engineering, 2010, 57, 1366-1376.	2.5	18
188	Comparison of Detection of Arrhythmias in Patients With Chronic Heart Failure Secondary to Non-Ischemic Versus Ischemic Cardiomyopathy by 1 Versus 7-Day Holter Monitoring. American Journal of Cardiology, 2010, 106, 677-681.	0.7	20
189	Impact of Kidney Dysfunction on Plasma and Urinary N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Acute Heart Failure. Congestive Heart Failure, 2010, 16, 214-220.	2.0	34
190	Soluble ST2 Monitoring Provides Additional Risk Stratification for Outpatients With Decompensated Heart Failure. Revista Espanola De Cardiologia (English Ed), 2010, 63, 1171-1178.	0.4	31
191	367: Lung Cancer after Heart Transplantation: Incidence and Prognosis. Data from the Spanish Post-Heart-Transplant Tumour Registry. Journal of Heart and Lung Transplantation, 2010, 29, S122-S123.	0.3	0
192	Reproducibility of echocardiographic measurements of epicardial fat thickness. International Journal of Cardiology, 2010, 141, 311-313.	0.8	51
193	Incidence and Risk Factors for Nonmelanoma Skin Cancer After Heart Transplantation. Transplantation Proceedings, 2010, 42, 3001-3005.	0.3	68
194	The Prognosis of Noncutaneous, Nonlymphomatous Malignancy After Heart Transplantation: Data From the Spanish Post-Heart Transplant Tumour Registry. Transplantation Proceedings, 2010, 42, 3011-3013.	0.3	14
195	Upper digestive bleeding due to Dieulafoy's lesion during the postoperative period of aortocoronary bypass surgery in a patient treated with clopidogrel. Revista Espanola De Enfermedades Digestivas, 2010, 102, 675.	0.1	0
196	Red blood cell distribution width predicts long-term outcome regardless of anaemia status in acute heart failure patients. European Journal of Heart Failure, 2009, 11, 840-846.	2.9	187
197	Risk Stratification of Mortality in Patients With Heart Failure and Left Ventricular Ejection Fraction >35%. American Journal of Cardiology, 2009, 103, 1003-1010.	0.7	53
198	Usefulness of Serial Monitoring of B-Type Natriuretic Peptide for the Detection of Acute Rejection After Heart Transplantation. American Journal of Cardiology, 2009, 103, 1149-1153.	0.7	29

#	ARTICLE	IF	CITATIONS
199	Complementary Prognostic Value of Cystatin C, N-Terminal Pro-B-Type Natriuretic Peptide and Cardiac Troponin T in Patients With Acute Heart Failure. <i>American Journal of Cardiology</i> , 2009, 103, 1753-1759.	0.7	88
200	Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients. <i>Clinical Transplantation</i> , 2009, 23, 329-336.	0.8	58
201	Soluble ST2 for Predicting Sudden Cardiac Death in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction. <i>Journal of the American College of Cardiology</i> , 2009, 54, 2174-2179.	1.2	205
202	Pulmonary Surfactant Protein B in the Peripheral Circulation and Functional Impairment in Patients With Chronic Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2009, 62, 136-142.	0.4	3
203	QRS Duration and Early Hemodynamic Instability After Coronary Revascularization Surgery. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2009, 62, 652-659.	0.4	1
204	Sex Hormone-Binding Globulin: A New Marker of Disease Severity and Prognosis in Men With Chronic Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2009, 62, 1381-1387.	0.4	13
205	The MUSIC Risk score: a simple method for predicting mortality in ambulatory patients with chronic heart failure. <i>European Heart Journal</i> , 2009, 30, 1088-1096.	1.0	194
206	Disfunci3n ventricular izquierda transitoria tras pericardiocentesis. Una complicaci3n infrecuente que es necesario conocer. <i>Revista Espanola De Cardiologia</i> , 2009, 62, 1071-1072.	0.6	3
207	Impact of Chronic Kidney Disease on Major Bleeding Complications and Mortality in Patients With Indication for Oral Anticoagulation Undergoing Coronary Stenting. <i>Chest</i> , 2009, 135, 983-990.	0.4	19
208	Comparison of Late Mortality in Hospitalized Patients >70 Years of Age With Systolic Heart Failure Receiving Beta Blockers Versus Those Not Receiving Beta Blockers. <i>American Journal of Cardiology</i> , 2008, 102, 1711-1717.	0.7	5
209	Malignancy After Heart Transplantation: Incidence, Prognosis and Risk Factors. <i>American Journal of Transplantation</i> , 2008, 8, 1031-1039.	2.6	129
210	¿Existe un lugar para levosimend3n en los servicios de urgencias hospitalarios?. <i>Revista Espanola De Cardiologia</i> , 2008, 61, 545-546.	0.6	1
211	Prognostic Value of BNP and Cardiopulmonary Exercise Testing in Patients With Systolic Heart Failure on Beta-Blocker Therapy. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2008, 61, 260-268.	0.4	1
212	Is There a Role for Levosimendan in Hospital Emergency Departments?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2008, 61, 545-546.	0.4	0
213	Troponin-T Monitoring in Outpatients With Nonischemic Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2008, 61, 678-686.	0.4	4
214	Positive association of anticytoskeletal endothelial cell antibodies and cardiac allograft rejection. <i>Human Immunology</i> , 2008, 69, 143-148.	1.2	29
215	Prognostic value of the Thrombolysis in Myocardial Infarction risk score in a unselected population with chest pain. Construction of a new predictive model. <i>American Journal of Emergency Medicine</i> , 2008, 26, 439-445.	0.7	8
216	Association of Blood Pressure and Its Evolving Changes With the Survival of Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2008, 14, 561-568.	0.7	16

#	ARTICLE	IF	CITATIONS
217	Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. <i>European Heart Journal</i> , 2008, 29, 1011-1018.	1.0	71
218	Increased Major Bleeding Complications Related to Triple Antithrombotic Therapy Usage in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Artery Stenting. <i>Chest</i> , 2008, 134, 559-567.	0.4	117
219	Letter by Pascual-Figal et al Regarding Article, "Anabolic Deficiency in Men With Chronic Heart Failure: Prevalence and Detrimental Impact on Survival" <i>Circulation</i> , 2007, 115, e548; author reply e549.	1.6	2
220	Left atrial enlargement and NT-proBNP as predictors of sudden cardiac death in patients with heart failure. <i>European Journal of Heart Failure</i> , 2007, 9, 802-807.	2.9	42
221	Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. <i>European Journal of Heart Failure</i> , 2007, 9, 518-524.	2.9	86
222	B-type natriuretic peptide release in the coronary effluent after acute transient ischaemia in humans. <i>Heart</i> , 2007, 93, 1077-1080.	1.2	9
223	Expression of HLA Molecules on Peripheral Blood Lymphocytes: A Useful Monitoring Parameter in Cardiac Transplantation. <i>Transplantation Proceedings</i> , 2007, 39, 2362-2364.	0.3	6
224	Gastrointestinal Complications in Heart Transplant Patients: MITOS Study. <i>Transplantation Proceedings</i> , 2007, 39, 2397-2400.	0.3	33
225	Influence of Induction Therapy, Immunosuppressive Regimen and Anti-viral Prophylaxis on Development of Lymphomas After Heart Transplantation: Data From the Spanish Post-Heart Transplant Tumour Registry. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 1105-1109.	0.3	41
226	Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure. <i>International Journal of Cardiology</i> , 2007, 120, 338-343.	0.8	36
227	Epidemiology and New Predictors of Atrial Fibrillation After Coronary Surgery. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2007, 60, 841-847.	0.4	6
228	Relation of B-Type Natriuretic Peptide Levels Before and After Exercise and Functional Capacity in Patients With Idiopathic Dilated Cardiomyopathy. <i>American Journal of Cardiology</i> , 2007, 99, 1279-1283.	0.7	16
229	The Relationship of Anti-MICA Antibodies and MICA Expression with Heart Allograft Rejection. <i>American Journal of Transplantation</i> , 2007, 7, 1842-1848.	2.6	104
230	Conferencia de Consenso de los Grupos Españoles de Trasplante Cardíaco. <i>Revista Espanola De Cardiologia Suplementos</i> , 2007, 7, 4B-54B.	0.2	19
231	78 Relation of loop diuretic dose to mortality in advanced heart failure and left ventricular systolic dysfunction. <i>European Journal of Heart Failure, Supplement</i> , 2007, 6, 16-16.	0.2	0
232	672 Anabolic deficiency as determinant of functional impairment and prognosis in heart failure patients. <i>European Journal of Heart Failure, Supplement</i> , 2007, 6, 146-146.	0.2	0
233	Preoperative Statin Therapy and Troponin T Predict Early Complications of Coronary Artery Surgery. <i>Annals of Thoracic Surgery</i> , 2006, 81, 78-83.	0.7	46
234	Soluble HLA-G in Heart Transplantation: Their Relationship to Rejection Episodes and Immunosuppressive Therapy. <i>Human Immunology</i> , 2006, 67, 257-263.	1.2	65

#	ARTICLE	IF	CITATIONS
235	The Predictive Value of Soluble Major Histocompatibility Complex Class I Chain-Related Molecule A (MICA) Levels on Heart Allograft Rejection. <i>Transplantation</i> , 2006, 82, 354-361.	0.5	44
236	Statins and Postoperative Risk of Atrial Fibrillation Following Coronary Artery Bypass Grafting. <i>American Journal of Cardiology</i> , 2006, 97, 55-60.	0.7	204
237	A systematic review of the literature on home monitoring for patients with heart failure. <i>Journal of Telemedicine and Telecare</i> , 2006, 12, 234-241.	1.4	121
238	Successful biventricular assistance after heart transplantation. <i>Annals of Thoracic Surgery</i> , 2004, 77, 720-721.	0.7	3
239	Effects of isolated obesity on systolic and diastolic left ventricular function. <i>British Heart Journal</i> , 2003, 89, 1152-1156.	2.2	251
240	Brugada-Like Electrocardiographic Pattern Induced by Fever. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2002, 25, 856-859.	0.5	105
241	Acute decompensated heart failure: current pharmacological approaches. <i>Research Reports in Clinical Cardiology</i> , 0, , 227.	0.2	0